However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

The revamp of French drugmaker Sanofi under new chief executive Paul Hudson has filtered up to top management, with four senior figures leaving the company. The move comes shortly after Hudson ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

“We reached almost 16% sales growth in the third quarter, illustrating the underlying strength of our portfolio,” said Sanofi CEO Paul Hudson, in a statement. “Our performance was boosted by ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials for next-generation drugs. CEO Paul Hudson's spending plans were ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned ... Sanofi CEO Paul Hudson said in a statement.

Before you buy stock in Sanofi, consider this ... [Operator instructions] And with this I'll now hand you over to Paul. Paul Hudson-- Chief Executive Officer Thank you, Thomas.